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Hypoxia causes the activation of eEF2K and induces eEF2 phosphorylation 19 
independently of previously-known inputs into eEF2K. Here, we show that eEF2K is 20 
subject to hydroxylation on proline-98. Proline hydroxylation is catalysed by proline 21 
hydroxylases, oxygen-dependent enzymes which are inactivated during hypoxia. 22 
Pharmacological inhibition of proline hydroxylases also stimulates eEF2 phosphorylation. 23 
Pro98 lies in a universally-conserved linker between the calmodulin-binding and catalytic 24 
domains of eEF2K. Its hydroxylation partially impairs the binding of calmodulin to eEF2K 25 
and markedly limits the CaM-stimulated activity of eEF2K. Neuronal cells depend on 26 
oxygen and eEF2K helps to protect them from hypoxia.  27 
eEF2K is the first example of a protein directly involved in a major energy-28 
consuming process to be regulated by proline hydroxylation. Since eEF2K is cytoprotective 29 
during hypoxia and other conditions of nutrient insufficiency, it may be a valuable target 30 
for therapy of poorly-vascularised solid tumours. 31 
 32 
33 
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Introduction:  34 
Many cells require aerobic metabolism to generate energy, necessitating an 35 
adequate supply of oxygen. Protein synthesis is a major energy-consuming process, 36 
especially translation elongation which uses both ATP (for amino acyl-tRNA charging) and 37 
GTP (at least two are used during each round of the elongation process). Overall, at least 38 
four ATP equivalents are used for each amino acid added to the growing chain during 39 
elongation. Elongation rates can be regulated through the phosphorylation of eukaryotic 40 
elongation factor 2 (eEF2) (43). Phosphorylation of eEF2 on Thr56 by eEF2 kinase 41 
(eEF2K) inhibits its ability to interact with ribosomes (7) thereby impairing translation 42 
elongation. Indeed, a range of studies has shown that increased phosphorylation of eEF2 is 43 
associated with slower ribosomal movement along the mRNA (e.g., (27,31,39)).  44 
eEF2K interacts with calmodulin (CaM) through a binding site which lies almost 45 
immediately N-terminal to its catalytic domain (12,37). The catalytic domain belongs to the 46 
small group of (six) mammalian α-kinases, rather than the main protein kinase superfamily; 47 
α-kinases show no sequence homology and only limited three-dimensional structural 48 
homology to other protein kinases (14,35). eEF2K activity is regulated through several 49 
signaling pathways linked, e.g., to nutrient availability; these include signaling through the 50 
mammalian target of rapamycin complex 1 (mTORC1), which represses eEF2K activity, 51 
and the AMP-activated protein kinase (AMPK), a key cellular energy sensor (20) which 52 
causes activation of eEF2K (3,22), probably in part by inhibiting mTORC1 signaling. Both 53 
inputs operate such that nutrient starvation activates eEF2K to inhibit eEF2 and slow down 54 
elongation. This, in turn, will help conserve ATP (and GTP, which are interconverted by 55 
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nucleoside diphosphate kinase) and amino acids, key precursors for protein production. 56 
Indeed, recent studies show that eEF2K plays a key role in the ability of cancer cells to 57 
cope with nutrient starvation and that they adapt to poor nutrient availability by switching 58 
on eEF2K (likely via AMPK) (31). To date, no substrates for eEF2K other than eEF2 have 59 
been reported. 60 
Oxygen starvation (hypoxia) also imposes a stress on many cells, e.g., by impairing 61 
ATP production by mitochondria (and other effects). Hypoxia is especially important in 62 
highly oxidative tissues such as heart muscle and brain, e.g., during cardiac ischemia or 63 
stroke. One important mechanism by which cells can respond to inadequate oxygen 64 
(hypoxia) involves the regulation of proteins by proline hydroxylation. Proline 65 
hydroxylation is catalysed by proline hydroxylases (PHDs), which require oxygen as co-66 
substrate (24). The best-known example of control of an intracellular protein by proline 67 
hydroxylation is the transcription factor hypoxia-inducible factor (HIF)-1α. During 68 
normoxia, proline hydroxylation of HIF1α renders it a substrate for the E3 ubiquitin-ligase 69 
von Hippel-Lindau, leading to its proteasome-mediated destruction (24). Hydroxylation of 70 
HIF1α is impaired during hypoxia, allowing its stabilisation and increasing its levels. This 71 
enhances the transcription of HIF1α target genes, which encode proteins that help cells 72 
withstand hypoxia, e.g., the glucose transporter Glut1 (17). Identifying proteins that are 73 
subject to proline hydroxylation is challenging and very few other intracellular proteins are 74 
so far known to be regulated by this modification. In particular, no PHD targets that 75 
regulate energy-demanding processes have previously been discovered. 76 
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Previous studies, in cardiomyocytes and in breast cancer cells, have shown that the 77 
phosphorylation of eEF2 increases during hypoxia and contributes to cell survival under 78 
these conditions (10,46). However, it was unclear whether eEF2K is actually activated 79 
under these conditions. More recently, it has been shown that inhibition of prolyl 80 
hydroxylases increases eEF2 phosphorylation (42), but again the mechanism remained 81 
unclear. Here we show that eEF2K is activated during hypoxia or upon inhibition of prolyl 82 
hydroxylases. We show that eEF2K is inhibited by its hydroxylation on a highly conserved 83 
proline residue, restricting its activity during normoxia. During hypoxia, when proline 84 
hydroxylation is impaired, eEF2K becomes more active to inhibit protein synthesis, thus 85 
protecting cells from hypoxia. This is the first example of direct regulation by proline 86 
hydroxylation of an enzyme involved in damping down a major energy-consuming process.  87 
88 
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Materials and Methods 89 
Antibodies and chemicals 90 
The mTOR inhibitors, rapamycin was purchased from Calbiochem (Nottingham, UK) and 91 
AZD8055 was purchased from Tocris. FG-4497 was synthesized at FibroGen, Inc. (San 92 
Francisco, CA). Where indicated, cells were exposed to the PHD inhibitor FG-4497 at 93 
indicated concentrations for indicated periods of time. Control conditions included 94 
exposure to equivalent concentrations of vehicle. All other chemicals and biochemicals 95 
were from Sigma unless otherwise indicated. Antibodies for anti-eEF2K human and mouse 96 
which were generously provided by the Division of Signal Transduction Therapy, 97 
University of Dundee, UK. Anti-FLAG was from Sigma and the anti-phospho-98 
eEF2(Thr56) antibody was generated by Eurogentec; all other antibodies were from Cell 99 
Signaling Technology. eEF2 for kinase assays was purified from HeLa cell cytoplasm 100 
(essentially as described in (26)).  101 
 102 
Cell culture and treatment 103 
Mouse embryonic fibroblasts (MEFs) from eEF2K-/- (knockout) mice and matched wild-104 
type counterparts were prepared from embryos at embryonic day 13.5. MEFs from eEF2K 105 
(WT) and eEF2K-/- mouse embryos were cultured in Dulbecco's modified Eagle's medium 106 
(DMEM; Invitrogen) supplemented with 10% foetal calf serum (FCS), and 100 units/mL 107 
penicillin, and 0.1 mg/mL streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 108 
5% CO2. TSC2–/–MEFs and the corresponding TSC2+/+ cell line were generously provided 109 
by Dr. David Kwiatkowski (Harvard University, Boston). HeLa cells were grown in 110 
DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) FBS (foetal 111 
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bovine serum), 2 mM glutamine and 1% penicillin/streptomycin. Colorectal 112 
adenocarcinoma HCT116 cells were generously provided by Janssen Pharmaceuticals and 113 
cultured using standard procedures in a 37°C humidified incubator with 5% CO2 in high-114 
glucose McCoy's 5A Modified Medium (Invitrogen) supplemented with 10% (v/v) foetal 115 
calf serum, 100 units/mL penicillin, and 0.1 mg/mL streptomycin. HEK (human embryonic 116 
kidney)-293 cells were cultured and transfected as described previously (19). Wild type 117 
(WT) and AMPKα1/α2 double knockout (DKO) MEFs (28) were generously provided by 118 
Dr Benoit Viollet (Institute Cochin, University of Paris). Cells were grown in DMEM 119 
(Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) fetal bovine serum, 2 120 
mM glutamine and 1% penicillin/streptomycin. 121 
 Human lung carcinoma A549 cell line containing an IPTG-inducible shRNA 122 
plasmid directed towards the eEF2K mRNA was generously provided by Janssen 123 
Pharmaceuticals and cells were cultured using standard procedures in a humidified 124 
incubator at 37°C with 5% CO2 in DMEM supplemented with 10% (v/v) FBS (fetal bovine 125 
serum), 1.5 mM glutamine, 100 units/mL penicillin and 0.1 mg/mL streptomycin. To 126 
induce knockdown of eEF2K, cells were cultured for 5 days with 1 mM isopropyl β-D-1-127 
thiogalactopyranoside (IPTG) prior to experimentation in order to induce the knockdown of 128 
eEF2K.  129 
 Primary cultures of cortical neurons were isolated as previously described (50). 130 
Cortices were isolated in ice cold Hanks’ balanced salt solution from P0 or P1 eEF2K-KO 131 
or WT mice. Tissue was gently minced and digested in Neurobasal medium (NM) 132 
containing papain (20 U/mL) and 0.32 mg/mL of L-cysteine at 37°C for 20 min followed 133 
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by 31°C for an additional 20 min. Tissue was then washed once in NM containing 1 mg/mL 134 
each of BSA and soybean trypsin inhibitor (STI) then incubated at 37°C for 2 min in NM 135 
containing 10 mg/mL each of BSA and STI. The dissociated tissue was then washed once 136 
in NM and triturated with fire-polished glass pipettes. Cells were then washed in NM and 137 
passed through a 40 μm cell strainer after which they were counted and plated onto poly-D-138 
lysine coated culture dishes at 1500-2000 cells/mm2. After 1 h, the overlying medium was 139 
removed and replaced with NM containing 2% B27 supplement, 0.5 mM L-glutamine and 140 
100 U/mL penicillin/streptomycin. One-half of the medium was replaced with fresh 141 
medium every 3-4 days. Cells were used in experiments at day-in-vitro 7. 142 
 Hypoxic culture conditions (1% or 0.1% (v/v) O2) were achieved in a custom-143 
designed hypoxic flush chamber (Billups and Rothenberg, Inc.) by infusion of a 144 
preanalyzed gas mixture (1% oxygen, 5% CO2, 94% N2 or 1000ppm oxygen/5% 145 
CO2/nitrogen 200 bar) (BOC Ltd.). All experiments were performed with exponentially 146 
growing cells that had been plated at approximately 60% cell density and then made 147 
hypoxic 18 to 24 h later.  148 
 149 
Cell lysis and analyses of samples 150 
For Western blot analyses, cells were extracted into buffer consisting of 50 mM β-151 
glycerophosphate, pH 7.5; 1 mM EGTA; 1 mM EDTA; 1% (v/v) Triton X-100; 1 mM 152 
Na3VO4; 0.1% (v/v) β-mercaptoethanol; protease inhibitors (leupeptin, pepstatin and 153 
antipain, each 1 μg/mL). Lysates were centrifuged at 13,000 rpm to remove debris. Protein 154 
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concentrations in the resulting supernatants were determined as described (2). In all cases, 155 
the same amount of total protein was applied to each lane of a given gel. 156 
 157 
158 
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Analysis of binding of eEF2K to CaM–Sepharose 159 
To study further the interaction of eEF2K with CaM, CaM–Sepharose-binding experiments 160 
were performed using wild-type GST–eEF2K, W99A, W99L and D97A. The expressed 161 
proteins were treated overnight at 4°C with PreScission protease (20 U/ml) to cleave the 162 
GST tag. Cleaved proteins were isolated by adding glutathione resin (GE Healthcare) to 163 
remove the PreScission protease and the cleaved GST tag. 1 µg of each sample, in 50 mM 164 
(pH 7.5) and 150 mM NaCl, was applied to CaM–Sepharose™ 4B (GE Healthcare) pre-165 
equilibrated in 50 mM MOPS (pH 7.5) and 150 mM NaCl; and either 2 mM CaCl2 or 4 166 
mM EDTA and incubated for 30 min at 4°C. The resin was washed three times with the 167 
appropriate buffer. Samples were analyzed by SDS-PAGE and western blotting using anti-168 
GST. 169 
 170 
Protein synthesis measurements 171 
Briefly, cells were incubated in the presence of [35S]methionine/cysteine to a final 172 
(radioactive) concentration of 10 μCi/ml for 30 min. After incubation, the medium was 173 
removed completely and the cells were washed with ice-cold PBS and lysed using a 174 
standard procedure (as described in Cell culture and treatment). The protein concentrations 175 
in the extracts measured using the Bradford method. Samples of lysate were applied to 176 
3MM filter papers (Whatman) and allowed to dry at room temperature. After three brief 177 
washes with 5% (w/v) trichloracetic acid, two at 100°C and one in ethanol, filters were 178 
again dried. Incorporated radioactivity was measured by scintillation counting. 179 
 180 
181 
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ATP measurements 182 
To assess ATP levels the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was 183 
used according to manufacturer’s instructions to quantitate the ATP present. 184 
 185 
Assays for eEF2 Kinase 186 
eEF2 kinase was assayed as described earlier (4) with the following modifications. HEK 187 
293 cells overexpressing eEF2K were harvested in high Ca2+ buffer (50 mM HEPES pH 188 
7.4; 50 mM NaCl; 50 mM β-glycerophosphate; 0.3% (w/v) CHAPS; and 1 mM CaCl2) in 189 
order to maintain the eEF2 kinase-CaM interaction. 10 ng of cell lysate was used per 190 
reaction in a total volume of 40 µl containing 20 mM 3-(N-morpholino)propanesulfonic 191 
acid (MOPS), pH 7.0; containing 5 mM MgCl2; 2 mM EDTA; 1 mM dithiothreitol; 2% 192 
(v/v) glycerol; 4.14 mM CaCl2/5 mM EGTA (free Ca2+ = 1 μM at pH 7) in the presence of 193 
purified eEF2 (2 μg) and [γ-32P]ATP. Activity was assayed at 30°C. The reaction was 194 
stopped by the addition of SDS-PAGE sample buffer, and the incorporation of 32P into 195 
eEF2 was determined by SDS-PAGE followed by staining the gel with Coomassie brilliant 196 
blue and fluororadiography using a Typhoon phosphorimager (GE Healthcare). To measure 197 
the activity of endogenous eEF2K, 1 μg of cell lysate was used per reaction. The eEF2 198 
kinase was IP’d with antibodies raised against either eEF2 kinase or the FLAG epitope, as 199 
appropriate, and beads were washed 4x in extraction buffer containing 1 mM Ca2+-ions. 200 
 201 
To assess the activity of recombinant eEF2K, GST-tagged eEF2K or point mutants were 202 
expressed in E. coli (Rosetta™(DE3)pLysS) and purified as previously described (38). 203 
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 204 
Assays of eEF2K activity were performed using buffer B [50 mM MOPS, pH 7.0 (unless 205 
stated otherwise), 20 μg/ml CaM (where present), 5 mM MgCl2, 14 mM 2-206 
mercaptoethanol, 0.67 mM CaCl2, 2 mM EDTA, 0.4 mM EGTA, 1 mM benzamidine, and 207 
1 mM each of leupeptin and pepstatin]. Reactions, in a total volume of typically 20 μl, 208 
contained 1 μg of purified eEF2 and were initiated by adding [γ-32P]ATP (final 209 
concentration 0.1 mM, 1 μCi per reaction). Reactions were incubated at 30°C for times up 210 
to 30 min and then SDS/PAGE sample buffer was added. Samples were immediately 211 
heated at 95°C for 5 min to denature the proteins and stop the reaction. Products were 212 
analysed by SDS/PAGE (10% gel) and, after staining with Coomassie Brilliant Blue, gels 213 
were placed into destain/fixing solution (50% (v/v) methanol and 10% (v/v) acetic acid). 214 
Gels were then placed on Whatman 3MM paper, covered with Saran wrap and dried on a 215 
vacuum gel dryer. Radioactivity was detected using a phosphorimager (Typhoon, GE 216 
Healthcare). 217 
 218 
Assays of eEF2K activity against the MH-1 peptide were performed in buffer B essentially 219 
as described (36) using 300 μM peptide and 100 ng of recombinant eEF2K. Filters were 220 
immediately placed in approximately 300 mL (for up to 25 filters) of 75 mM 221 
orthophosphoric acid and washed thrice more in similar volumes of the same. They were 222 
then rinsed in ethanol and dried in an oven at 100°C. Radioactivity was determined using 223 
the Čerenkov method. 224 
 225 
226 
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Isothermal titration calorimetry 227 
Isothermal titration calorimetry measurements were carried out using an iTC200 228 
MicroCalorimeter (GE Healthcare Bio-Sciences) at 25°C. eEF2K peptides corresponding to 229 
the wild-type eEF2K sequence (residues 78-100) were synthesized and purified to >95% 230 
purity (ChinaPeptides, Shanghai). Calmodulin and all peptides were prepared and dialyzed 231 
in the same buffer (20mM piperazine-N,N′-bis(2-ethanesulfonic acid), 150 mM KCl, 10 232 
mM CaCl2, pH 7.5). Ligand was titrated into protein solution at molar ratios of 10:1 233 
corresponding to approximately 220 μM ligand (peptide) and 19 μM protein (CaM). Each 234 
experiment consisted of a first injection of 0.3 μl followed by 39 injections of 1 μl of 235 
peptide solution into the cell, while stirring at 800 rpm. Control titrations (peptide into 236 
buffer) were measured. Data acquisition/analysis were performed using the Origin 237 
Scientific Graphing and Analysis software package (OriginLab). Data analysis was 238 
performed by generating a binding isotherm and best fit using the following parameters: N 239 
(number of sites), Δ H (cal/mol), Δ S (cal/mol/deg), and K (binding constant, M-1). 240 
 241 
Protein digestion, analysis by mass spectrometry and data processing. 242 
Proteomic analyses were carried out by the University of Leicester Proteomics Facility 243 
(PNACL). Bands of interest were excised from the gel, and in-gel trypsin digestion was 244 
carried out upon each (45). Each slice was destained using 200 mM ammonium 245 
bicarbonate/20% acetonitrile, followed by reduction (10 mM dithiothreitol, Melford 246 
Laboratories Ltd., Suffolk, UK), alkylation (100 mM iodoacetamide, Sigma, Dorset, UK) 247 
and enzymatic digestion with trypsin (sequencing grade modified porcine trypsin, Promega, 248 
Southampton, UK) in 50 mM triethylammonium bicarbonate (Sigma) using an automated 249 
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digestion robot (Multiprobe II Plus EX, Perkin Elmer, UK). After overnight digestion, 250 
samples were acidified using formic acid (final concentration 0.1% (v/v)). 251 
 252 
LC-MS/MS was carried out using an RSLCnano HPLC system (Dionex, UK) and an LTQ-253 
Orbitrap-Velos mass spectrometer (Thermo Scientific). Samples were loaded at high flow 254 
rate onto a reverse-phase trap column (0.3 mm i.d. x 1 mm), containing 5 μm C18 300 Å 255 
Acclaim PepMap medium (Dionex) maintained at a temperature of 37°C. The loading 256 
buffer was 0.1% formic acid / 0.05% trifluoroacetic acid / 2% acetonitrile. 257 
 258 
Peptides were eluted from the trap column at a flow rate of 0.3 µL/min and through a 259 
reverse-phase capillary column (75μm i.d. x 250mm) containing Symmetry C18 100 Å 260 
medium (Waters, UK) that was manufactured in-house using a high pressure packing 261 
device (Proxeon Biosystems, Denmark). The output from the column was sprayed directly 262 
into the nanospray ion source of the LTQ-Orbitrap-Velos mass spectrometer. 263 
 264 
The LTQ-Orbitrap-Velos mass spectrometer was set to acquire a 1 microscan FTMS scan 265 
event at 60000 resolution over the m/z range 350-1250 Da in positive ion mode. Accurate 266 
calibration of the FTMS scan was achieved using a background ion-lock mass for 267 
polydimethylcyclosiloxane (445.120025 Da). Subsequently up to 10 data dependent HCD 268 
MS/MS were triggered from the FTMS scan. The isolation width was 2.0 Da, normalized 269 
collision energy 40.0, and activation time 10 ms. Dynamic exclusion was enabled. 270 
 271 
272 
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Mutagenesis of eEF2K 273 
The cDNA encoding human eEF2K was cloned into a pcDNA3.1 vector for expression of 274 
FLAG-tagged eEF2K in HEK-293 cells. Mutagenesis of proline 96 or proline 98 in human 275 
eEF2 kinase to alanine was performed by PCR using “QuikChange®” (Stratagene). The 276 
forward primer for P96A was 5′- GAAGGCCAAGCACATGGCCGACCCCTGGGCTG -277 
3′, and the reverse primer for P96A was 5′- 278 
CAGCCCAGGGGTCGGCCATGTGCTTGGCCTTC-3′. The forward primer for P98A 279 
was 5′-GCACATGCCCGACGCCTGGGCTGAGTTC -3′, and the reverse primer for P98A 280 
was 5′-GAACTCAGCCCAGGCGTCGGGCATGTGC-3′.  281 
 282 
Reproducibility and statistical analysis of data.  283 
All experiments were conducted at least three times, with similar data being obtained in 284 
each case. For immunoblots, a typical set of data is shown in each case. Quantitation of 285 
immunoblot data was achieved using the LiCor Odyssey software.   286 
 287 
Numerical data are expressed as the mean ±S.E.M. for the indicated number of 288 
individual experiments. Wherever appropriate, the statistical significance of the data was 289 
assessed using a student’s t-test, a one-way ANOVA followed by Dunnets post test or a 290 
two-way ANOVA followed by a Bonferroni post-hoc test, as described in the figure 291 
legends, using Graph Pad prism 6 software. * <0.05, ** <0.01, *** <0.001, **** <0.0001. 292 
 293 
 294 
295 
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Results 296 
Hypoxia elicits a delayed increased in eEF2 phosphorylation 297 
Subjecting HCT116 colorectal carcinoma cells to hypoxia caused a small but consistent 298 
increase in eEF2 phosphorylation at 2h and a gradual, but more pronounced increase by 8-299 
16 h (Fig. 1A). Our findings are distinct from an earlier study which reported a rapid 300 
increase in eEF2K phosphorylation during hypoxia (42); our data also reveal the existence 301 
of a second, slower and much more marked rise in eEF2 phosphorylation. The rapid 302 
changes in eEF2 phosphorylation that they observed likely reflect different regulatory 303 
inputs into eEF2. 304 
Hypoxia also caused an increase in eEF2 phosphorylation in mouse embryonic 305 
fibroblasts (MEFs), HeLa cells or primary cortical neurons by similar times (Fig. 1B-D). 306 
This was not observed in cells from mice in which the EEF2K gene has been disrupted 307 
(Fig. 1B; see also Fig. 2A,B), indicating that hypoxia-induced eEF2 phosphorylation 308 
requires eEF2K (and is not catalysed by AMPK, which has been reported to phosphorylate 309 
eEF2 (21)). 310 
Although hypoxia (10,46) or inhibition of PHDs using dimethyloxalylglycine 311 
(DMOG) has previously been shown to increase eEF2 phosphorylation, through PHD2 312 
(42), the underlying mechanisms remain unknown. The delayed nature of this effect was of 313 
particular interest as hypoxia might increase the expression of eEF2K, e.g., at a 314 
transcriptional level via HIF1α, which mediates the induction of a gene expression program 315 
that helps cells adapt to hypoxia (34) or by stabilising the eEF2K protein itself (analogous 316 
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to the stabilisation of HIF1α). However, there was no significant increase in eEF2K protein 317 
levels in cells subjected to hypoxia (Fig. 1A-C); if anything, in some cases, eEF2K levels 318 
actually fell (Fig. 1A), as seen under other conditions where eEF2K is activated (27,49). 319 
Thus, the hypoxia-induced phosphorylation of eEF2 does not appear to result from 320 
stabilisation of eEF2K or induction of its expression. The simplest alternative explanation 321 
is that the intrinsic activity of eEF2K increases during hypoxia and this is examined below.  322 
Hypoxia-induced phosphorylation of eEF2 does not require signaling via AMPK or 323 
mTORC1 324 
We first explored whether known upstream regulators of eEF2K were involved in 325 
the hypoxia-induced increase in eEF2 phosphorylation. Members of the p38 MAP kinase 326 
family are often activated during cell stresses and can phosphorylate eEF2K, although they 327 
provide a negative input to eEF2K activity rather than stimulating it (25,26). Nevertheless, 328 
we examined whether p38 MAPK was activated (phosphorylated) during hypoxia in 329 
HCT116 cells, MEFs and HeLa cells. A transient increase was seen in HCT116 cells, well 330 
before the rise in eEF2 phosphorylation, and no change was seen in the other cells tested 331 
(Fig. 1A-C).  332 
Hypoxia and the consequent ATP depletion can stimulate AMPK which can, in 333 
turn, activate eEF2K (3,22). For example, hypoxia caused a delayed activation of AMPK in 334 
HCT116 cells, as judged from the phosphorylation of a well-established AMPK substrate, 335 
acetyl-CoA carboxylase (ACC; Fig. 1A), although this appeared to lag behind the increase 336 
in phospho-eEF2 suggesting it may not be a causative event in regulating eEF2 here. An 337 
 18 
 
inhibitor of AMPK, MRT199665 (9), did not prevent the hypoxia-induced phosphorylation 338 
of eEF2 (Fig. 3A). Furthermore, hypoxia still increased eEF2 phosphorylation in AMPKα 339 
double-knockout cells (Fig. 3B). Thus, the hypoxia-induced phosphorylation of eEF2 is 340 
independent of AMPK, ruling out that it is directly mediated by AMPK or via, e.g., 341 
AMPK-induced inactivation of mTORC1 signaling (18,23). We noted that the levels of 342 
eEF2K protein and EEF2K mRNA are both lower in AMPK-DKO cells (Fig. 3B,C), 343 
suggesting that AMPK that may positively regulate eEF2K expression. 344 
 345 
Inhibition of proline hydroxylases induces the phosphorylation of eEF2 independently of 346 
altered mTORC1 or AMPK signaling 347 
To explore how PHDs regulate eEF2 and eEF2K, we made use of the PHD inhibitor 348 
DMOG. Treatment of HCT116 or HeLa cells with DMOG increased the phosphorylation of 349 
eEF2, often markedly (Fig. 1E,F; and 3D,E,G). However, eEF2K levels did not increase, 350 
similar to the situation in hypoxia (Fig. 1A-C). Since DMOG affects both prolyl 351 
hydroxylases and related enzymes such as asparaginyl hydroxylase, we also tested the 352 
effects of a specific PHD inhibitor, FG-4497 (41). FG-4497 also enhanced eEF2 353 
phosphorylation in HeLa cells (Fig. 1G). Since use of FG-4497 requires that cells are 354 
maintained in lower serum (2%) than usual (10%), which itself tends to raise p-eEF2 levels, 355 
the increase caused by FG-4497 is less than seen with DMOG (which can be used on cells 356 
in higher serum concentrations). However, the final level of p-eEF2 is similar with either 357 
reagent, confirming that DMOG affects eEF2 phosphorylation by inhibiting PHDs. 358 
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DMOG was also unable to increase eEF2 phosphorylation in A549 cells where 359 
eEF2K had been knocked down using shRNA (Fig. 3D) or in eEF2K-/- MEFs (Fig. 3E), 360 
showing that here the phosphorylation of eEF2 is also mediated by eEF2K. The effect of 361 
DMOG was relatively slow, typically requiring 4-6 h. In contrast, AZD8055 (8), which 362 
blocks the mTOR pathway that negatively regulates eEF2K activity (39), induced a faster 363 
increase in eEF2 phosphorylation (Fig. 3G). This is consistent with the effect of DMOG not 364 
being due to impaired mTORC1 signaling, a point which is explored in detail below, 365 
although alternative explanations are possible. It should also be noted that, while hypoxia 366 
did decrease mTORC1 signaling in HCT116 cells (as judged from the decrease in 367 
phosphorylation of ribosomal protein S6 at Ser240/244, well-known substrates for the p70 368 
S6 kinases which are activated by mTORC1; Fig. 1A), this effect was much more rapid 369 
than the rise in phospho-eEF2, which is inconsistent with a direct link between them. 370 
The robust induction of eEF2 phosphorylation by DMOG in HCT116 cells was not 371 
blocked by MRT199665 (9) again indicating that AMPK is not involved (Fig. 3F). 372 
However, DMOG did increase the phosphorylation of acetyl-CoA carboxylase, an AMPK 373 
substrate, and MRT199665 blocked this (Fig. 3F), implying that DMOG increases AMPK 374 
activity; although the mechanism underlying this is unclear. AMPK is activated by 375 
phosphorylation (at Thr172) by the protein kinase LKB1, which is not present in HeLa cells 376 
(47). DMOG failed to activate AMPK in this cell-type, as judged by the phosphorylation 377 
status of its substrate ACC (Fig. 1F), indicating that the effect of DMOG on AMPK 378 
probably requires LKB1. 379 
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Hypoxia or DMOG can each impair mTORC1 signaling via the HIF1α-mediated 380 
induction of REDD1, a positive regulator of the TSC1/TSC2 complex that inhibits 381 
mTORC1 signaling (5,15). Since mTORC1 signaling negatively regulates eEF2K, hypoxia 382 
or DMOG might induce eEF2 phosphorylation by relieving this inhibitory input from 383 
mTORC1. In HCT116 colorectal carcinoma cells, MEFs and HeLa cells, hypoxia or 384 
DMOG treatment did indeed inhibit mTORC1 signaling, as judged by the decreased 385 
phosphorylation of ribosomal protein S6 (RpS6; Fig. 1A,C,F), a substrate for the S6 kinases 386 
which are activated by mTORC1, and of 4E-BP1, another mTORC1 substrate (Fig. 1C). 387 
Since the effects of hypoxia on mTORC1 signaling are mediated via the TSC1/2 complex 388 
(5), we used TSC2-null cells to eliminate this input. Hypoxia or DMOG did not affect S6 389 
phosphorylation in TSC2-/- MEFs, but still induced the phosphorylation of eEF2 (Fig. 390 
4A,B), albeit more slowly, without the initial rise, likely reflecting the high activity of 391 
mTORC1 signaling (and lower eEF2k activity) in these cells. This implies the slow phase 392 
of the effect of DMOG is not mediated via impaired mTORC1 signaling. PHDs also play a 393 
role in the activation of mTORC1 signaling by amino acids (15). However, DMOG did not 394 
affect mTORC1 signaling (S6 phosphorylation) in TSC2-/- cells where this input is still 395 
intact, therefore the increased phosphorylation of eEF2 does not reflect this role of PHDs in 396 
cellular regulation. Taken together, these data demonstrate that hypoxia and DMOG 397 
treatment enhance eEF2 phosphorylation independently of inhibition of mTORC1 398 
signaling. 399 
 400 
401 
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eEF2K mRNA levels can be reciprocally regulated by mTORC1 and hypoxia 402 
We noted that eEF2K protein levels are lower in TSC2-/- MEFs than in wild-type 403 
cells and that, in these cells, they did increase following DMOG treatment (Fig. 4A). To 404 
study this further, we measured the levels of the EEF2K mRNA. EEF2K mRNA levels 405 
were markedly lower in TSC2-/- cells than wild-type MEFs (Fig. 4C), and increased in 406 
response to DMOG treatment in TSC2-/- but not in WT MEFs (Fig. 4C). These effects, seen 407 
only in TSC2-/- cells where mTORC1 signaling is very active, suggest that DMOG may 408 
counter an inhibitory effect of hyperactivated mTORC1 signaling on eEF2K expression. 409 
DMOG induced another HIF1α-regulated mRNA, GLUT1, to a similar degree in both cell 410 
lines, i.e., irrespective of their TSC2 status (Fig. 4D). Acroflavine, which inhibits HIF1α 411 
dimerization (29), blocked the DMOG-induced rise in eEF2K levels (Fig. 4E), suggesting 412 
this increase is mediated via HIF1α. However, analysis of the promoter region of the 413 
mouse EEF2K gene failed to reveal any consensus binding sites for HIF1α.  414 
Thus, the expression of the mRNA for EEF2K is probably regulated in multiple 415 
ways, e.g., downstream of AMPK, and in some settings by mTORC1 signaling and HIF1α; 416 
further work, beyond the scope of this study, is required to define the mechanisms involved 417 
here. 418 
 419 
420 
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Hypoxia or DMOG-treatment enhances the intrinsic activity of eEF2K 421 
Our data show that, in cells other than the single example of TSC2-null MEFS, 422 
hypoxia or DMOG treatment enhance eEF2 phosphorylation without increasing the levels 423 
of eEF2K protein. This suggested that the intrinsic activity of eEF2K may be enhanced 424 
under this condition. To test this, we assayed eEF2K activity in lysates of HeLa or HCT166 425 
cells, with or without an episode of hypoxia. As shown in Fig. 5A, hypoxia did indeed 426 
increase eEF2K activity. Similarly, higher eEF2K activity was observed following 427 
treatment of HEK293 cells or MEFs with DMOG although total levels of eEF2K were 428 
unchanged (Fig. 5B-D). To confirm conclusively that this change did reflect the activation 429 
of eEF2K, not, e.g., stimulation of a (hypothetical) alternative kinase or a change in 430 
phosphatase activity against eEF2, eEF2K was immunoprecipitated (IP’d) from MEF 431 
lysates prior to the assay, under mild conditions, and in the presence of Ca2+-ions, where 432 
CaM remains associated with eEF2K (4). Again, higher activity was observed in samples 433 
from DMOG-treated cells than in untreated controls (Fig. 5D; right hand part), confirming 434 
that treating cells with DMOG does increase the activity of eEF2K. It should be noted that 435 
the data for DMOG and for TSC2-/- MEFs (e.g., Fig. 4A,B) rule out inputs to the increase in 436 
eEF2K activity from other effects of hypoxia or impaired mTORC1 signaling, respectively.  437 
Finally, it was possible, as is the case in response to elevated cAMP levels (40), that 438 
eEF2K activity became independent of Ca2+-ions in DMOG-treated cells. However, eEF2K 439 
activity still showed a strong requirement for Ca2+-ions in samples from DMOG-treated 440 
cells (Fig. 5B).  441 
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eEF2K is subject to hydroxylation on a highly conserved proline 442 
Given that neither mTORC1 nor AMPK was involved in the effects reported here, 443 
and that eEF2K levels were not increased by DMOG or hypoxia, we examined whether 444 
eEF2K is itself subject to hydroxylation. To do this, eEF2K was immunoprecipitated from 445 
normoxic cells and then subjected to tryptic digestion followed by mass spectrometric 446 
analysis. This revealed the presence of one peptide, i.e., HMPDPWAEFHLEDIATER, that 447 
showed a mass shift of 32 Da, which is equivalent to two additional oxygen atoms (mass of 448 
observed peptide, 2224.8, compared to the mass predicted from the sequence, 2192.35). 449 
Inspection of the mass spectrum shows that one of these oxygen atoms corresponds to the 450 
oxidation of the only methionine in this peptide (cf. Table 1) which can occur during 451 
sample preparation. The hydroxylated peptide was observed in five separate experiments 452 
with material from normoxic cells, whereas the non-hydroxylated version of the peptide 453 
was not observed under this condition. The peptide identified corresponds to a region 454 
between the CaM-binding motif (12,37) and the catalytic domain of eEF2K. It contains two 455 
proline residues, Pro96 and Pro98 (Fig. 6A).  456 
It was important to pinpoint which proline in this peptide is modified. Fig. 6B 457 
shows a theoretical spectrum based on this peptide where either Pro96 (yielding peptide 458 
y16+2H) or Pro98 (y14+2H) is considered to be hydroxylated. The data in Fig. 6C and 459 
Table 1 show the y-ion series appearing at y14 m/z = 865.4 (2+) and the b-ion series at b5 460 
m/z = 305.6 (2+). This assigns the hydroxylation event unambiguously to proline 98 and 461 
rules out hydroxylation of Pro96 or any other similar modification, such as double 462 
oxidation of methionine to the sulfone (Table 1).  463 
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Samples of eEF2K derived from cells subjected to hypoxia for 24 h (to allow 464 
replacement of hydroxylated eEF2K by the non-hydroxylated protein) showed only a 465 
lighter version of this peptide, which unlike that from normoxic cells, was not hydroxylated 466 
on either proline residue. These data show that this peptide, and Pro98 in particular, is not 467 
hydroxylated under hypoxic conditions.  468 
Pro98 and the two adjacent residues are highly conserved among vertebrate eEF2K 469 
sequences and, strikingly, given the low overall sequence identity in this region of eEF2K, 470 
are even conserved in eEF2K from nematode worms (Table 2). Given that Pro98 is close to 471 
the CaM binding site, we asked whether treating cells with DMOG, to prevent 472 
hydroxylation, affected the ability of CaM to activate eEF2K.  473 
Cells were transfected with a vector encoding FLAG-tagged eEF2K. To ensure that, 474 
where appropriate, that none of the eEF2K under study was hydroxylated, cells were 475 
treated with DMOG for the entire period during which the ectopic eEF2K was expressed. 476 
Lysates were prepared using buffer containing Ca2+-ions (where some CaM remains 477 
associated with eEF2K). Under these conditions eEF2K from DMOG-treated cells showed 478 
higher activity than from control cells (Fig. 7A, top part); since expression of FLAG-479 
eEF2K is much higher than the endogenous protein (Fig. 7B, right hand part), the assay 480 
reflects the activity of the FLAG-eEF2K.  481 
This difference between control and DMOG-treated samples could reflect decreased 482 
association of eEF2K with CaM or lower ability of CaM to activate eEF2K. To evaluate 483 
this, excess CaM was added to lysates from control or DMOG-treated cells; this strongly 484 
stimulated eEF2K activity towards eEF2 (Fig. 7A, middle part). Importantly, even in the 485 
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presence of excess CaM, the activity of eEF2K from DMOG-treated cells was substantially 486 
higher than that of eEF2K from control cells (Fig. 7A), where Pro98 is hydroxylated. This 487 
indicates that CaM is less able to stimulate eEF2K from control cells where Pro98 is 488 
hydroxylated. 489 
Similarly, in lysates from MEFs, addition of a large amount of CaM to the assay did 490 
not eliminate the difference in activity of eEF2K from control vs. DMOG-treated cells (Fig. 491 
5D). The clear implication of these data is that hydroxylation of eEF2K likely impairs the 492 
extent to which CaM stimulate eEF2K, thus limiting its activity. 493 
To test specifically the role of hydroxylation of Pro98 in controlling eEF2K activity, 494 
Pro98 was mutated to alanine, which cannot be hydroxylated and is otherwise probably the 495 
most similar residue to proline. We also created eEF2K[Pro96Ala] as a (negative) control. 496 
The WT and mutant eEF2K proteins expressed at similar levels in HEK293 cells and their 497 
expression was not affected by DMOG treatment, confirming that PHD inhibition does not 498 
alter the stability of eEF2K (Fig. 7B). Since FLAG-eEF2K protein levels were much higher 499 
than those of endogenous eEF2K (Fig. 7B, right hand part), we could reliably assess 500 
FLAG-eEF2K activity in cell lysates (where sufficient CaM is already present). DMOG 501 
pre-treatment of the cells caused similar increases in the activity of WT and eEF2K[P96A] 502 
(Fig. 7C,D). In contrast, the activity of eEF2K[P98A] was already higher than that of wild-503 
type eEF2K in samples from normoxic cells and, more importantly, DMOG did not 504 
increase it further (Fig. 7C,D). The activities of WT eEF2K and eEF2K[P98A] were strictly 505 
dependent upon Ca/CaM in control and DMOG-treated conditions (Fig. 7E). These data 506 
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suggest that hydroxylation of Pro98 under normoxic conditions limits eEF2K activity, 507 
while the absence of hydroxylation permits a higher level of activity. 508 
 509 
Hydroxylation of Pro98 impairs binding of eEF2K to CaM and its activation by CaM  510 
The proximity of Pro98 to the CaM-binding site suggested its hydroxylation might 511 
affect eEF2K’s interaction with CaM. We therefore used isothermal titration calorimetry 512 
(ITC) to study the binding of CaM to synthetic peptides including the CaM-binding site of 513 
eEF2K; we used peptides corresponding to residues 78-100 of human eEF2K and 514 
containing, at the position equivalent to residue 98, either proline or hydroxyproline. The 515 
unmodified peptide bound to CaM with an affinity of 66±9 nM, while binding to 78-516 
100(HO-Pro98) was somewhat weaker (Kd, 123±3 nM; Fig. 8A,B; Table 3), showing that 517 
the hydroxylation of Pro98 does interfere with CaM binding, but only modestly. To assess 518 
whether hydroxylation affected the overall ability of eEF2K to bind CaM, HEK293 cells 519 
were transfected with a vector for FLAG-eEF2K. eEF2K was IP’d from control or DMOG-520 
treated cells (Fig. 8C). No difference was observed in the amount of CaM which co-521 
purified with the FLAG-tagged eEF2K, consistent with modest change in the affinity for 522 
CaM shown by the ITC data. 523 
If the altered affinity of eEF2K for CaM sufficed to explain its control by proline 524 
hydroxylation/DMOG, then adding additional, saturating levels of CaM should overcome 525 
the difference in the affinity for CaM of eEF2K from control compared to hypoxic or 526 
DMOG-treated cells. However, the data reported in Figs. 6D, 8C show that adding excess 527 
 27 
 
CaM did not bring the activity of eEF2K from control cells up to the higher level seen for 528 
DMOG-treated cells, indicate that binding of CaM to eEF2K does not limit its activity here. 529 
Thus, the hydroxylation of Pro98 probably restricts the activity of eEF2K by decreasing its 530 
capacity to be fully activated by CaM and/or its maximal activity. 531 
As noted above, Pro98 lies in the ‘linker’ region between the CaM-binding- and 532 
catalytic domains of eEF2K, which is strongly conserved across vertebrate eEF2K 533 
sequences suggesting it might play an important role (Fig. 6A). Indeed, Pro98 and its 534 
flanking residues (Asp97 and Trp99 in human eEF2K) are even conserved in eEF2K from 535 
distantly-related nematodes. To test the roles of these residues, we mutated them to 536 
alanines, and also, more conservatively, mutated W99 to leucine, another hydrophobic 537 
residue. eEF2K[W97A], [W99A] and [W99L] all still bound to CaM (Fig. 8D), likely 538 
because they lie beyond the identified CaM binding site. In contrast, in the presence of 539 
CaM, these mutants each showed substantially lower activity than WT eEF2K against MH-540 
1, an established peptide substrate for eEF2K (37) (Fig. 8E). Indeed, eEF2K[W99A] almost 541 
entirely failed to undergo activation by Ca2+/CaM when its activity was assessed against 542 
this peptide or eEF2 (Fig. 8E,F). Thus, these highly conserved residues in the ‘linker’ 543 
region between the CaM-binding site and the catalytic domain apparently play a key role in 544 
coupling CaM binding to the stimulation of eEF2K activity, consistent with a role of 545 
hydroxylation of Pro98 in influencing the activation of eEF2K by CaM. 546 
Taken together, our data indicate that hydroxylation of Pro98 both somewhat 547 
weakens the binding of eEF2K to CaM and impairs the ability of CaM to fully activate 548 
eEF2K (or its maximal activity). Thus, even when eEF2K is assayed in the presence of 549 
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excess CaM, hydroxylation of Pro98 still limits its maximal activity, thereby restraining 550 
eEF2K activity during normoxia.  551 
Since there is no known mechanism to reverse proline hydroxylation (24), the 552 
enhancement of eEF2K activity during hypoxia requires the replacement of the pre-existing 553 
hydroxylated eEF2K by newly-made, more active non-hydroxylated eEF2K protein. 554 
Importantly, the rate of accumulation of new (in this case FLAG-tagged) eEF2K is 555 
comparable to that of the hypoxia- or DMOG-induced increase in eEF2 phosphorylation 556 
(Fig. 9; cf. Fig. 1). Previous data indicate that eEF2K has a relatively short half-life (1). The 557 
nature of this control mechanism presumably explains why the effects of hypoxia or 558 
DMOG on eEF2 phosphorylation are relatively slow.  559 
eEF2K aids the survival of neuronal cells during hypoxia 560 
The activation of eEF2K that occurs during hypoxia is expected to restrain the rate 561 
of elongation and thereby help cells cope with the available energy supply. We therefore 562 
tested whether eEF2K plays a role in helping cells to withstand hypoxia. This condition has 563 
a particularly pronounced impact on cells or tissues which depend heavily upon oxidative 564 
metabolism (e.g., cardiomyocytes, neurons). Cardiac muscle and brain undergo oxygen 565 
deprivation during ischemia or stroke. eEF2K has previously been shown to protect 566 
cardiomyocytes against hypoxic damage (46). We therefore tested its importance in another 567 
oxygen-dependent cell-type, primary neuronal cultures from wild-type or eEF2K-/- mice. 568 
Following hypoxia, eEF2K-/- neurons showed greater depletion of ATP and increased 569 
cleavage of poly ADP-ribose polymerase (PARP) (16) compared to wild-type cells (Fig. 570 
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10A,B). This indicates that eEF2K is cytoprotective in primary neurons as reported 571 
previously for cancer cell lines (10) (Fig. 10B). These data are consistent with the finding 572 
that, in neuronal cells subjected to hypoxia, inhibiting protein synthesis using carbimazole 573 
(which induces eEF2 phosphorylation), or other agents, preserved ATP content and 574 
prevented cell damage (30). These data underline the importance of eEF2K for resistance to 575 
oxygen deprivation. Interestingly, recent work has revealed that eEF2K is cytoprotective 576 
during nutrient starvation (31). This key role for eEF2K in helping cells withstand nutrient 577 
deficiency likely reflects the facts that protein synthesis consumes a large proportion of the 578 
energy generated by oxidative metabolism (6) and that eEF2 phosphorylation inhibits 579 
translation elongation, reducing the energy demands.  580 
It was important to assess whether the observed phosphorylation of eEF2 was 581 
associated with inhibition of protein synthesis. It is not possible to do this for hypoxia, 582 
since opening the hypoxic chamber to add the radiolabel admits oxygen, abrogating the 583 
hypoxia. It was therefore more appropriate to study the effect of DMOG; however, this 584 
generally impairs mTORC1 signaling, which in turn controls other components of the 585 
translational machinery, making it impossible to interpret data from wild-type (or even 586 
eEF2K-/-) MEFs. To avoid this complication, we used TSC2-/- MEFs, where DMOG affects 587 
neither mTORC1 signaling (as assessed by the phosphorylation of S6) nor the 588 
phosphorylation of eIF2, another key regulator of protein synthesis (Fig. 10C). DMOG 589 
substantially inhibited protein synthesis in TSC2-/- MEFs (Fig. 10D), consistent with the 590 
concept that the phosphorylation of eEF2 serves to restrict ATP consumption, thereby 591 
favouring cell survival. It is important to note that the complete inhibition of protein 592 
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synthesis during hypoxia is inappropriate given that it is crucial that for some proteins to 593 
continue to be made to allow cells to adapt to this condition (e.g., HIF1α; see (48)). 594 
595 
 31 
 
Discussion 596 
Here we describe the first example of oxygen-dependent proline hydroxylation 597 
regulating a protein (eEF2K) that is directly involved in regulating a major energy-598 
consuming process (protein synthesis). Hydroxylation of eEF2K during normoxia restrains 599 
its activity, such that its activity is enhanced during hypoxia, a response that will serve to 600 
decrease the demand for ATP and GTP for translation elongation. Importantly, Pro98 is not 601 
hydroxylated in eEF2K from hypoxic or DMOG-treated cells. eEF2K is also the first 602 
protein kinase whose activity is known to be regulated by proline hydroxylation; although 603 
IκB kinase-β is also subject to this modification, it appears primarily to regulate the levels 604 
of this kinase rather than its intrinsic activity (11). Two very recent studies showed that 605 
ribosomal protein S23 is subject to proline hydroxylation (33,44), but, unlike the effects 606 
reported here, this modification is appears not to be involved in the overall control of 607 
translation during hypoxia. 608 
The fact that the modified residue in eEF2K, Pro98, and neighbouring residues are 609 
completely conserved through evolution from nematodes to primates suggests this is an 610 
ancient mechanism for regulating protein synthesis in response to oxygen deficiency. Our 611 
findings also point to a key role for residues in the linker region between the CaM-binding 612 
site in eEF2K and its catalytic domain in its activation by CaM. Given the high demand of 613 
protein synthesis for cellular energy (6), it makes clear physiological sense that hypoxia 614 
should induce the phosphorylation and inhibition of eEF2 to reduce the energy needs of 615 
protein synthesis. Ideally, it would be useful to show that WT eEF2K inhibits protein 616 
synthesis to a lesser extent than the Pro98Ala mutant during normoxic conditions within 617 
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cells; however, more active mutants of eEF2K inhibit their own synthesis (or that of a co-618 
transfected reporter) which are therefore expressed at markedly lower levels than for less 619 
active variants (13,36). This unfortunately makes it very hard to interpret the data from 620 
such experiments. 621 
Our findings also reveal that the level of expression of the EEF2K mRNA is lower 622 
in cells lacking active AMPK or with hyperactivated mTORC1 signaling, pointing to 623 
transcriptional control of eEF2K expression by nutrient-sensitive signaling pathways. 624 
Interestingly, nutrient deprivation increases the expression of the EEF2K mRNA in 625 
mammalian cells and in C. elegans (31), consistent with enhanced expression of this 626 
cytoprotective kinase as a widespread response to lack of nutrients. In contrast, oxygen 627 
deprivation or inhibition of PHDs did not increase the levels of eEF2K, except in the single 628 
example of TSC2-/- cells, where constitutive mTORC1 signaling normally appears to 629 
repress eEF2K expression. Oxygen availability thus generally appears to promote the 630 
activation, rather than the expression level, of eEF2K. 631 
The replacement of pre-existing, hydroxylated and less active eEF2K by more 632 
active, non-hydroxylated eEF2K presumably allows cells to adapt to low oxygen 633 
conditions, such that enhancement of eEF2K activity no longer has to rely on inputs from 634 
inhibition of mTORC1 or activation of AMPK. This resets the activity of eEF2K, and thus 635 
eEF2 phosphorylation, at a higher level, providing a mechanism to allow cells to adapt to 636 
reduced oxygen availability by stably enhancing the activity of a protein kinase that slows 637 
down translation elongation. The activation of AMPK or inhibition of mTORC1 signaling, 638 
which can each acutely activate eEF2K, likely serves to provide short-term modulation of 639 
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eEF2K activity. The long-term adaptive response revealed in this study is distinct from the 640 
rapid responses to PHD inhibition reported recently (42). 641 
These data, together with earlier findings showing cytoprotective roles for eEF2K in 642 
hypoxic cardiac muscle cells (10) and in response to starvation for amino acids and glucose 643 
(see, e.g., (31)), indicate that eEF2K helps to defend cells against the adverse effects of 644 
deficiencies in diverse nutrients. eEF2K may therefore be a useful target in tackling poorly-645 
vascularised solid tumors, regions of which may become hypoxic, and require eEF2K to 646 
allow cell survival (32). 647 
648 
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FIGURE LEGENDS:  836 
Fig. 1. Hypoxia or DMOG treatment induces phosphorylation of eEF2 in diverse cell 837 
types. (A-F) The indicated cells were subjected to hypoxia or treated with DMOG (1 mM) 838 
for the indicated times. Cell lysates were subjected to western blot analysis using the 839 
indicated antibodies. The graph in (A) shows quantitation of data from multiple 840 
experiments, data are given as mean ± SEM (control cells without hypoxia =1; n = 3). Data 841 
were analysed using a one-way ANOVA. (G) HeLa cells were exposed to FG-4497 for 6 h 842 
at the concentrations indicated in the figure. Cell lysates were subjected to western blot 843 
analysis using the indicated antibodies. The graph in (G) shows quantitation of data from 844 
three experiments, data are given ± SEM (control cells without treatment =1). The positive 845 
control for P-p38 MAP kinase is a sample from bone marrow-derived macrophages treated 846 
with lipopolysaccharide. 847 
Fig. 2. eEF2K knockout strategy. Generation of an eEF2K conditional knockout allele 848 
(A) Murine eEF2K gene map and targeting vector. Rectangles represent the coding exons 849 
of the eEF2K gene as well as the FRT sites and the neomycin resistance (Neo) cassette. The 850 
targeting vector can be linearized with NotI (B) Genotyping of littermates. 851 
Fig. 3. Hypoxia induced eEF2K activation is independent of AMPK. (A) HCT116 cells 852 
were subjected to hypoxia (0.1% oxygen) for 16 h in the presence or absence of the AMPK 853 
inhibitor MRT199665 (MRT). (B) WT or AMPK α1/α2 DKO MEFs were subjected to 854 
hypoxia (0.1% oxygen) 16 h. Cell lysates were subjected to western blot analysis using the 855 
indicated antibodies. (C) eEF2K mRNA levels were determined by RT-qPCR and 856 
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normalized to 18S rRNA. Data were analysed using an unpaired t-test. The inset shows 857 
western blot analysis of lysates of WT and AMPK-DKO MEFs; equal amounts of total 858 
protein were applied to the gel. The blots were developed using the indicated antibodies. 859 
(D) A549 cells were cultured in the presence or absence of 1 mM IPTG for 5 days to induce 860 
the knockdown of eEF2K. Cells were then treated with DMOG (1 mM) or AZD8055 (A8) 861 
(1 µM) for the times indicated in the figure. (E) Wild-type (eEF2K+/+) or eEF2K knockout 862 
(eEF2K-/-) MEFs were treated with DMOG (1 mM), or with AZD8055 (A8) (1 μM), for the 863 
indicated times. ‘0’ indicates samples from cells that had been pre-incubated with or 864 
without MRT199665 for 30 min.Samples from  cells incubated for 8h without DMOG were 865 
also analysed. Lysates were analysed by immunoblots as indicated. (F) HCT116 cells were 866 
treated with DMOG (1 mM) with/without the AMPK inhibitor MRT199665 for the times 867 
indicated. Cell lysates were subjected to western blot analysis using the indicated 868 
antibodies. ACC, acetyl-CoA carboxylase. (G) HCT116 cells were treated with DMOG (1 869 
mM) or AZD8055 (1 µM) for the times indicated in the figure. Cell lysates were subjected 870 
to western blot analysis using the indicated antibodies. 871 
Fig. 4. Hypoxia or DMOG induce eEF2 phosphorylation independently of changes in 872 
mTORC1 signaling. (A) TSC2+/+ or TSC2-/- MEFs were treated with DMOG (1 mM) for 873 
the indicated times or (B) subjected to hypoxia (0.1%) for 16 h. Equal amounts of cell 874 
lysates were analysed by SDS-PAGE/western blot using the indicated antibodies. The 875 
graph in (A) shows quantitation of data from multiple experiments, data are given as mean 876 
± SEM (control cells without DMOG =1; n = 3). Data were analysed using an unpaired t-877 
test. In (C) and (D), TSC2+/+ and TSC2-/- MEFs were treated with 1 mM DMOG for 16 h. 878 
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EEF2K and GLUT1 mRNA levels were determined by RT-qPCR respectively following 879 
DMOG treatment. Data are shown as mean ± SEM, n = 3 normalized to 18S rRNA. Data 880 
were analysed using a two-way ANOVA. In (E), where indicated, cells were treated with 881 
DMOG (1 mM) in the presence or absence of acriflavine (ACF; 5 μM). Equal amounts of 882 
cell lysate were analysed by SDS-PAGE/western blot using the indicated antibodies. 883 
Fig. 5. Hypoxia or DMOG-treatment enhance the intrinsic activity of eEF2K. (A-D), 884 
the indicated cells were treated with DMOG or subjected to hypoxia (16h) and eEF2K 885 
activity was determined either in whole cell lysates (WCL; A,C) or after IP of FLAG-886 
tagged eEF2K (B; in the presence or absence of Ca2+ as indicated). The immunoblot below 887 
shows total eEF2K levels in lysates from control or DMOG-treated cells. (C) MEFs were 888 
treated for 6 h with DMOG and cell lysates were subjected to western blot analysis using 889 
the indicated antibodies. (D) eEF2K activity was determined in whole cell lysates or, after 890 
IP, in the presence or absence of CaM. Shown are phosphorimages of the corresponding 891 
SDS gels. 892 
Fig. 6. eEF2K is subject to hydroxylation on a highly-conserved proline residue. (A) 893 
(Top) Schematic depiction of the overall layout of eEF2K; the sequence of the CaM-894 
binding site and adjacent residues is shown; Pro98 is indicated in red. (Bottom) sequences 895 
of the identified CaM-binding site in eEF2K proteins from the indicated species. Positions 896 
of Pro98 (bold, capital) and Trp99 (capital) are indicated. (B) A predicted mass spectrum 897 
plotted using the m/z values shown in Table 2 showing two potential sites for proline 898 
hydroxylation. (C) A representative MS/MS spectrum shows fragmentation of the 899 
HMPDPWAEFHLEDIATER peptide. A mass identical to a hydroxyproline-containing 900 
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fragment is observed, representing the HM(OH)PDP(OH)WAEFHLEDIATER peptide. A 901 
+32 Da mass shift is observed in the peptide from eEF2K under normoxic conditions; m/z 902 
= 2224.8 compared to the mass predicted from the sequence 2192.35. The spectrum shows 903 
the y ion series appearing at y14 m/z = 865.4 (2+) and y16 m/z 971.5 (+2) which assigns 904 
hydroxylation unambiguously to proline 98. The pertinent peaks are indicated (arrows).  905 
 906 
Fig. 7. Hydroxylation on Proline-98 limits eEF2K activity. (A) HEK293 cells were 907 
transfected with a vector encoding FLAG-tagged eEF2K and, where shown, treated with 908 
DMOG (1 mM) for the entire period from transfection to lysis (20 h). Cells were lysed in 909 
extraction buffer containing CHAPs with calcium to maintain the CaM-eEF2K interaction. 910 
Cell lysates were assayed with or without CaM for 10 min using eEF2 as substrate. Data 911 
are phosphorimages of the corresponding SDS gels. Total eEF2K levels (WCL) were 912 
analysed by western blotting using anti-FLAG. (B-D) FLAG-tagged wild-type eEF2K or 913 
the [P96A] or [P98A] mutants were expressed in HEK293 cells which were subsequently 914 
treated with DMOG (6 h, 1 mM) where indicated. Immunoblot (IB) analyses using anti-915 
FLAG (left side; also anti-tubulin) or anti-eEF2K, from lysates of cells ectopically 916 
expressing FLAG-eEF2K or non-transfected cells (endogenous eEF2K). In (C,D), (FLAG)-917 
eEF2K activity was determined against eEF2 ± added calmodulin; in (D), data for assays 918 
conducted without added CaM; mean ±SEM, n=3. (E) FLAG-tagged wild-type eEF2K or 919 
the [P98A] mutant were expressed in HEK293 cells which were subsequently treated with 920 
DMOG (6 h, 1 mM) where indicated. Cells were lysed in extraction buffer containing 921 
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CHAPs and calcium to maintain the CaM-eEF2K interaction. Cell lysates were assayed 922 
with or without calcium and CaM for 10 min using eEF2 as substrate. 923 
 924 
Fig. 8. Effect of hydroxylation of Pro98 on binding to CaM and of selected mutations 925 
at this position on eEF2K activity. (A,B) Isothermal calorimetry experiments were 926 
performed as described in the Experimental section using (A) unmodified peptide and (B) 927 
peptide hydroxylated on Pro98. The top graphs represent the original titration curve and 928 
bottom graphs show the resulting binding isotherm. (C) DMOG treatment of cells does not 929 
significantly the copurification of CaM and eEF2K. HEK 293 cells were transfected with a 930 
vector encoding FLAG-eEF2K. They were then maintained for 48 h in the presence or 931 
absence of 1mM DMOG from the point of transfection. Cells were lysed, and 932 
immunoprecipitations were carried out in a modified extraction buffer containing 1 mM 933 
CaCl2 to maintain eEF2K-CaM interactions as described in Materials and Methods. The 934 
FLAG-tagged eEF2 kinase was immunoprecipitated from 200 μg of lysate protein using 935 
immobilized FLAG antibody and then subjected to SDS-PAGE followed by Western 936 
blotting for total eEF2 kinase or bound CaM. Blots for each protein are from non-adjacent 937 
lanes of the same gel. (D) The abilities of eEF2K and the indicated mutants to bind CaM 938 
were tested by affinity chromatography using CaM-Sepharose, using wild-type (WT) or the 939 
W99A, W99L or D97A mutants of bacterially-expressed eEF2K from which the GST tag 940 
had been removed by PreScission protease cleavage, as described in the Experimental 941 
section. Assays were conducted in the presence of CaCl. 1µg of cleaved WT eEF2K and 942 
mutant proteins were used in the pull-down with CaM resin and samples of the proteins 943 
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(0.1µg) were run to display equal input levels. Samples were analysed by immunoblots 944 
using anti-eEF2K antibodies; the migration positions of GST-eEF2K and cleaved eEF2K 945 
are shown.  (E) Activity of wild-type recombinant eEF2K or indicated mutants towards the 946 
MH1 peptide. Data are shown as mean ± SEM; n = 3. ***, P < 0.001 ****, P < 0.0001. P 947 
values were obtained using a two-way ANOVA compared with WT followed by 948 
Bonferroni post-tests. (F) Activity of wild-type or eEF2K[W99A] against eEF2. The upper 949 
part is a phosphorimage of the Coomassie-stained gel shown below. 950 
 951 
Fig. 9. Time course for the synthesis of new eEF2K molecules. HEK293 cells were 952 
transfected with a vector encoding FLAG-eEF2K; 24 h later, cells were treated with 953 
cycloheximide (10 μg/mL) for 16 h, followed by release into cycloheximide-free medium 954 
for the indicated times. Cell extracts were prepared and run on SDS-PAGE, followed by 955 
Western blot using anti–FLAG and anti–tubulin antibodies. 956 
 957 
Fig. 10. Loss of eEF2K compromises the ability of primary neuronal cells to withstand 958 
hypoxia. (A,B) primary neuronal cultures from control or eEF2K-knockout mice were 959 
maintained in culture for 7 days and then subjected to hypoxia (0.1% O2, 20 h). ATP levels 960 
were measured using a CellTiter-Glo® Luminescent Cell Viability kit (A) or western blots 961 
performed for the indicated proteins (B). The graph in (B) shows the levels of cleaved 962 
PARP (n = 3, ±SEM; level of cleaved PARP in wild-type cells subjected to hypoxia is set 963 
at 1). Data were analysed using a two-way ANOVA. (C) TSC2-/- MEFS were treated with 964 
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DMOG (1 mM), rapamycin (200 nM) or cycloheximide (10 µg/ml) for 6 h and lysed. 965 
Samples were analysed by immunoblots using the indicated antibodies. (D) TSC2-/- MEFS 966 
were treated with DMOG (1 mM) (6 h) and then incubated with 35S-methionine/cysteine 967 
(for the final 30 min). Samples were processed to measure incorporation of radiolabel into 968 
protein; data are shown ±SEM (n=3). Data were analysed using an unpaired t-test.  969 
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Table 1. m/z values for ions derived from the HMPDPWAEFHLEDIATER peptide. 
(A) B- and y-ions for the above peptide from eEF2K from normoxic cells (hydroxyproline 98 is highlighted).  
(B) Table of amino acid residue masses for the HMPDPWAEFHLEDIATER peptide, to assist with 
interpretation of the b- and y-ion series. Doubly-charged ions are indicated by, e.g., B + 2H. 
(A) 
B B ions B + 2H Amino acid Y ions Y + 2H Y 
1 138.1 69.5 H 2226 1113.5 18 
2 285.1 143.1 M + 16 2088.9 1045 17 
3 382.2 191.6 P 1941.9 971.5 16 
4 497.2 249.1 D 1844.8 922.9 15 
5 610.2 305.6 P +16 1729.8 865.4 14 
6 796.3 398.7 W 1616.8 808.9 13 
7 867.3 434.2 A 1430.7 715.8 12 
8 996.4 498.7 E 1359.7 680.3 11 
9 1143.5 572.2 F 1230.6 615.8 10 
10 1280.5 640.8 H 1083.5 542.3 9 
11 1393.6 697.3 L 946.5 473.7 8 
12 1522.6 761.8 E 833.4 417.2 7 
13 1637.7 819.3 D 704.4 352.7 6 
14 1750.8 875.9 I 589.3 295.2 5 
15 1821.8 911.4 A 476.2 238.6 4 
16 1922.8 961.9 T 405.2 203.1 3 
17 2051.9 1026.4 E 304.2 152.6 2 
18 2260 1113.5 R 175.1 88.1 1 
 
(B)  
b b Ions Amino acid Mass y Ions y 
1 137.1412 H 137.1412 2176.397 18 
2 268.3398 M 131.1986 2039.256 17 
3 365.4565 P 97.1167 1908.058 16 
4 480.5451 D 115.0886 1810.941 15 
5 577.6618 P  97.1167 1695.852 14 
6 763.8751 W 186.2133 1598.736 13 
7 834.9539 A 71.0788 1412.522 12 
8 964.0694 E 129.1155 1341.443 11 
9 1111.246 F 147.1766 1212.328 10 
10 1248.3872 H 137.1412 1065.151 9 
11 1361.5467 L 113.1595 928.0101 8 
12 1490.6622 E 129.1155 814.8506 7 
13 1605.7508 D 115.0886 685.7351 6 
14 1718.9103 I 113.1595 570.6465 5 
15 1789.9891 A 71.0788 457.487 4 
16 1891.0942 T 101.1051 386.4082 3 
17 2020.2097 E 129.1155 285.3031 2 
18 2176.3973 R 156.1876 156.1876 1 
 
Table 2. The sequence adjacent to the CaM-binding region, which contains the hydroxylated residue, 
Pro98, in eEF2K is highly conserved. 
 
Residues shaded in grey are conserved between all vertebrate eEF2K sequences shown, and in some cases in 
eEF2K from nematodes. The first tryptophan is essential for binding of eEF2K to CaM (Diggle et al., 1999). 
Residues shown white on a black background are completely conserved in all species; the proline within this 
sequence corresponds to Pro98 of human eEF2K. 
Mammals 
Homo sapiens  KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Pan troglodytes KEAWKHAIQKAKQ-MPDPWAEFHLEDIA 
Callithrix jacchus KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Mus musculus   KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Cricetulus griseus KEAWKHAIQKAKQ-MPDPWAEFHLEDIA 
Oryctolagus cuniculus KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Bos taurus  KEAWKHAIEKAKQ-MPDPWAEFHLEDVA 
Tursiops truncates KEAWKHAIEKAKQ-MPDPWAEFHLEDVA 
Equus caballus  KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Loxodonta africana KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Heterocephalus glaber KEAWKHAIQKAKQ-MPDPWAEFHLEDIA 
Felis catus  KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Dasypus novemcinctus KEAWKHAIEKAKQ-MPDPWAEFHLEDIA 
Sarcophilus harrisii QETWKHAIEKAKQ-MPDPWAEFHLEDIE 
Birds 
Gallus gallus  RETWKHAIEKAKQ-MPDPWAEFHLEDIE 
Anas platyrhynchos KETWKHAIEKAKQ-MPDPWAEFHLEDIE 
Meleagris gallopavo KETWKHAIEKAKQ-MPDPWAEFHLEDIE 
Fish 
Maylandia zebra RATWLHAIEKAKA-MPDPWAQFHLEEIA 
Danio rerio  KATWKHAIEKAKA-MPDPWAEFHLEEME 
Reptile 
Anolis carolinensis KEAWKHAIEKAKQ-MPDPWAEFHLEEIE 
Amphibian 
Xenopus tropicalis KEAWKHAIQKAKQ-MPDPWAEFHLEDIE 
Nematodes 
C. elegans            METWRKAARRARTNYIDPWDEFNIHEY 
C. briggsae         METWRRAARRARSNYVDPWDEFNIHEY 
 
Table 3. Isothermal titration calorimetry data for the interaction of Ca
2+
/CaM with eEF2K-based 
peptides  
 
Peptide Kd (nM) H (kcal/ 
mol) 
S at 
298K 
(cal/mol) 
-TS 
(kcal/ 
mol) 
G 
(kcal/ 
mol) 
N 
 
Number 
of expts 
eEF2K 
78-100 
 
66  9.38 -15.2  0.70 -18.4 -5.49 -9.76 0.99  0.035 3 
eEF2K 
78-100 
HO-Pro98 
123  2.64 -14.8  0.18 -18.2 -5.43 -9.43 0.99  0.007 3 
 
Table of thermodynamic parameters obtained by fitting the ITC data to a single-state binding model (N = 
stoichiometry of the interaction determined in the experiment, Kd = dissociation constant, ΔH = change in 
enthalpy, ΔS =change in entropy, and ΔG = Gibb's free energy obtained by calculation of ΔG =ΔH - TΔS. Data 
are expressed as mean values  standard deviation.  
 
